Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
10374 | 1069 | 37.4 | 66% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
171 | 3 | MONASCUS//CITRININ//MONASCUS PURPUREUS | 58457 |
419 | 2 | STATINS//EZETIMIBE//SIMVASTATIN | 16502 |
10374 | 1 | FENOFIBRATE//FENOFIBRIC ACID//FIBRATES | 1069 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | FENOFIBRATE | authKW | 1186816 | 17% | 23% | 182 |
2 | FENOFIBRIC ACID | authKW | 687385 | 4% | 63% | 38 |
3 | FIBRATES | authKW | 603247 | 11% | 17% | 121 |
4 | BEZAFIBRATE | authKW | 230825 | 5% | 16% | 49 |
5 | INTERNAL MED CLIN PHARMACOL | address | 134149 | 3% | 16% | 29 |
6 | MIXED DYSLIPIDEMIA | authKW | 127991 | 1% | 41% | 11 |
7 | CIPROFIBRATE | authKW | 124202 | 2% | 23% | 19 |
8 | MICRONIZED FENOFIBRATE | authKW | 93473 | 1% | 55% | 6 |
9 | FIBRATE THERAPY | authKW | 85689 | 0% | 100% | 3 |
10 | ST NIKOLAUS STIFTSHOSP GMBH | address | 85689 | 0% | 100% | 3 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Cardiac & Cardiovascular System | 5101 | 28% | 0% | 296 |
2 | Pharmacology & Pharmacy | 3246 | 33% | 0% | 355 |
3 | Peripheral Vascular Diseases | 2231 | 14% | 0% | 149 |
4 | Medicine, General & Internal | 953 | 15% | 0% | 161 |
5 | Endocrinology & Metabolism | 832 | 12% | 0% | 126 |
6 | Medicine, Research & Experimental | 342 | 8% | 0% | 83 |
7 | Chemistry, Medicinal | 88 | 3% | 0% | 37 |
8 | Medical Laboratory Technology | 60 | 1% | 0% | 16 |
9 | Toxicology | 21 | 2% | 0% | 23 |
10 | Chemistry, Analytical | 18 | 3% | 0% | 36 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | INTERNAL MED CLIN PHARMACOL | 134149 | 3% | 16% | 29 |
2 | ST NIKOLAUS STIFTSHOSP GMBH | 85689 | 0% | 100% | 3 |
3 | BEZAFIBRATE INFARCT PREVENT STUDY COORDINATING CT | 59500 | 0% | 42% | 5 |
4 | ISRAELI SOC PREVENT HEART ATTACKS | 51411 | 0% | 60% | 3 |
5 | ROND POINT NATION | 32129 | 0% | 38% | 3 |
6 | BIOMEDICUM CARDIOL | 28563 | 0% | 100% | 1 |
7 | BIOTR OULU | 28563 | 0% | 100% | 1 |
8 | CARDIOL CLIN TRIALS UNIT | 28563 | 0% | 100% | 1 |
9 | CARDIOL HEALTHY HEART PROGRAM | 28563 | 0% | 100% | 1 |
10 | CARDIOL SERV LIPID CLIN | 28563 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | ATHEROSCLEROSIS | 17613 | 8% | 1% | 81 |
2 | ARTERY | 6499 | 1% | 2% | 11 |
3 | JOURNAL OF CLINICAL LIPIDOLOGY | 6304 | 1% | 2% | 12 |
4 | CARDIOVASCULAR DIABETOLOGY | 5174 | 1% | 1% | 15 |
5 | NOUVELLE PRESSE MEDICALE | 4165 | 1% | 1% | 12 |
6 | CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL | 3691 | 2% | 1% | 25 |
7 | AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS | 3311 | 1% | 2% | 7 |
8 | PHARMACOLOGICAL REPORTS | 3102 | 1% | 1% | 14 |
9 | CLINICAL LIPIDOLOGY | 2680 | 1% | 2% | 6 |
10 | PROGRESS IN DRUG METABOLISM | 2595 | 0% | 9% | 1 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | FENOFIBRATE | 1186816 | 17% | 23% | 182 | Search FENOFIBRATE | Search FENOFIBRATE |
2 | FENOFIBRIC ACID | 687385 | 4% | 63% | 38 | Search FENOFIBRIC+ACID | Search FENOFIBRIC+ACID |
3 | FIBRATES | 603247 | 11% | 17% | 121 | Search FIBRATES | Search FIBRATES |
4 | BEZAFIBRATE | 230825 | 5% | 16% | 49 | Search BEZAFIBRATE | Search BEZAFIBRATE |
5 | MIXED DYSLIPIDEMIA | 127991 | 1% | 41% | 11 | Search MIXED+DYSLIPIDEMIA | Search MIXED+DYSLIPIDEMIA |
6 | CIPROFIBRATE | 124202 | 2% | 23% | 19 | Search CIPROFIBRATE | Search CIPROFIBRATE |
7 | MICRONIZED FENOFIBRATE | 93473 | 1% | 55% | 6 | Search MICRONIZED+FENOFIBRATE | Search MICRONIZED+FENOFIBRATE |
8 | FIBRATE THERAPY | 85689 | 0% | 100% | 3 | Search FIBRATE+THERAPY | Search FIBRATE+THERAPY |
9 | RESIDUAL CARDIOVASCULAR RISK | 60478 | 1% | 35% | 6 | Search RESIDUAL+CARDIOVASCULAR+RISK | Search RESIDUAL+CARDIOVASCULAR+RISK |
10 | BEZAFIBRATE PHARMACOKINETICS | 57126 | 0% | 100% | 2 | Search BEZAFIBRATE+PHARMACOKINETICS | Search BEZAFIBRATE+PHARMACOKINETICS |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | MCKEAGE, K , KEATING, GM , (2011) FENOFIBRATE A REVIEW OF ITS USE IN DYSLIPIDAEMIA.DRUGS. VOL. 71. ISSUE 14. P. 1917 -1946 | 78 | 55% | 45 |
2 | KEATING, GM , (2011) FENOFIBRATE A REVIEW OF ITS LIPID-MODIFYING EFFECTS IN DYSLIPIDEMIA AND ITS VASCULAR EFFECTS IN TYPE 2 DIABETES MELLITUS.AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. VOL. 11. ISSUE 4. P. 227-247 | 72 | 54% | 24 |
3 | KEATING, GM , CROOM, KF , (2007) FENOFIBRATE - A REVIEW OF ITS USE IN PRIMARY DYSLIPIDAEMIA, THE METABOLIC SYNDROME AND TYPE 2 DIABETES MELLITUS.DRUGS. VOL. 67. ISSUE 1. P. 121-153 | 70 | 50% | 85 |
4 | GUAY, DRP , (1999) MICRONIZED FENOFIBRATE: A NEW FIBRIC ACID HYPOLIPIDEMIC AGENT.ANNALS OF PHARMACOTHERAPY. VOL. 33. ISSUE 10. P. 1083-1103 | 78 | 60% | 48 |
5 | NAJIB, J , (2002) FENOFIBRATE IN THE TREATMENT OF DYSLIPIDEMIA: A REVIEW OF THE DATA AS THEY RELATE TO THE NEW SUPRABIOAVAILABLE TABLET FORMULATION.CLINICAL THERAPEUTICS. VOL. 24. ISSUE 12. P. 2022-2050 | 60 | 61% | 48 |
6 | TZIOMALOS, K , ATHYROS, VG , (2006) FENOFIBRATE: A NOVEL FORMULATION (TRIGLIDE (TM)) IN THE TREATMENT OF LIPID DISORDERS: A REVIEW.INTERNATIONAL JOURNAL OF NANOMEDICINE. VOL. 1. ISSUE 2. P. 129-147 | 88 | 36% | 25 |
7 | FILIPPATOS, T , MILIONIS, HJ , (2008) TREATMENT OF HYPERLIPIDAEMIA WITH FENOFIBRATE AND RELATED FIBRATES.EXPERT OPINION ON INVESTIGATIONAL DRUGS. VOL. 17. ISSUE 10. P. 1599-1614 | 57 | 44% | 30 |
8 | BALFOUR, JA , MCTAVISH, D , HEEL, RC , (1990) FENOFIBRATE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES AND THERAPEUTIC USE IN DYSLIPIDEMIA.DRUGS. VOL. 40. ISSUE 2. P. 260-290 | 60 | 70% | 133 |
9 | SAHEBKAR, A , WATTS, GF , (2014) ROLE OF SELECTIVE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR MODULATORS IN MANAGING CARDIOMETABOLIC DISEASE: TALE OF A ROLLER-COASTER.DIABETES OBESITY & METABOLISM. VOL. 16. ISSUE 9. P. 780 -792 | 47 | 43% | 11 |
10 | TSIMIHODIMOS, V , LIBEROPOULOS, E , ELISAF, M , (2009) PLEIOTROPIC EFFECTS OF FENOFIBRATE.CURRENT PHARMACEUTICAL DESIGN. VOL. 15. ISSUE 5. P. 517-528 | 72 | 32% | 17 |
Classes with closest relation at Level 1 |